Scientists at UW Medicine and the NIH have created an experimental flu vaccine that spurs broad immunity in animal trials
Researchers have developed experimental flu shots that protect animals from a wide variety of seasonal and pandemic influenza strains. The vaccine product is currently being advanced toward clinical testing. If proven safe and effective, these next-generation influenza vaccines may replace current seasonal options by providing protection against many more strains that current vaccines do not adequately cover.
A study detailing how the new flu vaccines were designed and how they protect mice, ferrets, and nonhuman primates appears in the March 24 edition of the journal Nature. This work was led by researchers at the University of Washington School of Medicine and the Vaccine Research Center part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
Influenza virus causes an estimated 290,000–650,000 deaths per year. Available flu vaccines, which need to be taken seasonally, often fail to protect against many circulating flu strains that cause illness, and the threat of another influenza pandemic looms.
“Most flu shots available today are quadrivalent, meaning they are made from four different flu strains. Each year, the World Health Organization makes a bet on which four strains will be most prevalent, but those predictions can be more or less accurate. This is why we often end up with ‘mismatched’ flu shots that are still helpful but only partially effective,” said lead author Daniel Ellis, a research scientist in the laboratory of Neil King. King is an assistant professor of biochemistry at the UW School of Medicine and a researcher at the Institute for Protein Design at UW Medicine.
To create improved influenza vaccines, the team attached hemagglutinin proteins from four different influenza viruses to custom-made protein nanoparticles. This approach enabled an unprecedented level of control over the molecular configuration of the resulting vaccine and yielded an improved immune response compared to conventional flu shots. The new nanoparticle vaccines, which contain the same four hemagglutinin proteins of commercially available quadrivalent influenza vaccines, elicited neutralizing antibody responses to vaccine-matched strains that were equivalent or superior to the commercial vaccines in mice, ferrets, and nonhuman primates. The nanoparticle vaccines—but not the commercial vaccines —also induced protective antibody responses to viruses not contained in the vaccine formulation. These include avian influenza viruses H5N1 and H7N9, which are considered pandemic threats.
The responses that our vaccine gives against strain-matched viruses are really strong, and the additional coverage we saw against mismatched strains could lower the risk of a bad flu season,” said Ellis.
Original Article: Nanoparticle flu shot blocks seasonal and pandemic strains
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Experimental flu vaccine
- What Merck’s Experimental COVID Pill Can and Can’t Do
The drug, molnupiravir, is named after Thor’s hammer, Mjölnir. But its power depends on reaching the right people, in the right time frame.
- Assessing the In Vitro Fitness of an Oseltamivir-Resistant Seasonal A/H1N1 Influenza Strain Using a Mathematical Model
In 2007, the A/Brisbane/59/2007 (H1N1) seasonal influenza virus strain acquired the oseltamivir-resistance mutation H275Y in its neuraminidase (NA) gene. Although previous studies had demonstrated ...
- Fauci Calls Merck's Experimental COVID-19 Pill 'Really Quite Impressive'
The White House chief medical adviser stressed, however, that such a pill should in no way replace getting vaccinated against the virus.
- Drugmaker Merck says experimental pill cuts worst effects of COVID-19
Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials ...
- Merck says experimental pill cuts COVID-19 hospitalizations and deaths by half
The drugmaker said early results showed patients who received molnupiravir within five days of COVID-19 symptoms showed clear benefits. The drug did not benefit patients already hospitalized with ...
Go deeper with Google Headlines on:
Experimental flu vaccine
Go deeper with Bing News on:
Nanoparticle flu vaccine
- Team creates liquid metal coating for fabrics
An international team led by researchers from North Carolina State University has created an antiviral, antimicrobial liquid metal coating for fabrics. The team, which also included researchers from ...
- Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
NanoFlu™ is a quadrivalent recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine produced in Novavax' SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein ...
- Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax ...
- Sanofi refocuses COVID-19 efforts away from mRNA
Trial data validates Sanofi’s mRNA and lipid nanoparticle platform but the company will not pursue its own mRNA COVID-19 vaccine Paris-based Sanofi has announced positive interim results from its ...
- Sanofi announces positive results from phase 1/2 study of mRNA-based Covid-19 vaccine candidate
Positive interim results from a phase 1/2 study of Sanofi’s mRNA-based Covid-19 vaccine candidate confirm the potential of recently-acquired Translate Bio’s messenger RNA (mRNA) and lipid nanoparticle ...